Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Hypertension

Free Subscription Articles published in Lancet Retrieve available abstracts of 35 articles: HTML format

Single Articles

August 2026
1. BALASUBRAMANIAN A, Mathai SC
   Ralinepag in pulmonary arterial hypertension: a step forward.
   Lancet. 2026;408:492-493.
   PubMed    
   
   
   July 2026
2. MCLAUGHLIN VV, Solum D, Lachant D, Ataya A, et al
   Ralinepag for the treatment of pulmonary arterial hypertension (ADVANCE OUTCOMES): a randomised, double-blind, placebo-controlled phase 3 study.
   Lancet. 2026 Jul 28:S0140-6736(26)01011-1. doi: 10.1016/S0140-6736(26)01011.
   PubMed     Abstract available
   
   
   
3. 
   Metabolic traits in obesity and normal BMI in industrialised countries: a multi-country analysis of national population-based studies.
   Lancet. 2026 Jul 1:S0140-6736(26)00758-0. doi: 10.1016/S0140-6736(26)00758.
   PubMed     Abstract available
   
   
   May 2026
4. POULTER NR, Beaney T, Kerr GK, Kiru G, et al
   The role of community-based blood pressure screening in improving hypertension care.
   Lancet. 2026 May 6:S0140-6736(26)00379-X. doi: 10.1016/S0140-6736(26)00379.
   PubMed     Abstract available
   
   
   April 2026
5. ZENG G, Bidel Z, Yang Q, Canoy D, et al
   Pharmacological blood-pressure lowering for the prevention of cardiovascular disease and death across the full spectrum of chronic kidney disease severity: an individual-participant data meta-analysis.
   Lancet. 2026;407:1626-1638.
   PubMed     Abstract available
   
   
   March 2026
6. KASUJJA FX, Aikaeli F, Garrib A, van Widenfelt E, et al
   Integrated community-based versus facility-based care for people with HIV, diabetes, and hypertension in sub-Saharan Africa (INTE-COMM): an open-label, multicountry, cluster-randomised trial.
   Lancet. 2026;407:1084-1094.
   PubMed     Abstract available
   
   
   
7. AZIZI M, Brown JM, Dwyer JP, Flack JM, et al
   Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial.
   Lancet. 2026;407:988-999.
   PubMed     Abstract available
   
   
   
8. MAHFOUD F, Lauder L
   Aldosterone synthase inhibition in resistant hypertension: promises and unknowns.
   Lancet. 2026;407:922-923.
   PubMed    
   
   
   February 2026
9. AZIZI M, Tuttle KR, Brown JM, Piskorz DL, et al
   New drug therapies for hypertension.
   Lancet. 2026 Feb 10:S0140-6736(25)02064-1. doi: 10.1016/S0140-6736(25)02064.
   PubMed     Abstract available
   
   
   November 2025
10. FARRAR J, Frieden T
    WHO global report on hypertension 2025.
    Lancet. 2025;406:2318-2319.
    PubMed    
    
    
    August 2025
11. WANG N, Salam A, Pant R, Kumar A, et al
    Blood pressure-lowering efficacy of antihypertensive drugs and their combinations: a systematic review and meta-analysis of randomised, double-blind, placebo-controlled trials.
    Lancet. 2025;406:915-925.
    PubMed     Abstract available
    
    
    
12. MCEVOY JW
    Optional hypertension: a new concept emerging from trials of intensive blood pressure control.
    Lancet. 2025 Aug 28:S0140-6736(25)01670-8. doi: 10.1016/S0140-6736(25)01670.
    PubMed    
    
    
    
13. GUO X, Sun G, Xu Y, Zhou S, et al
    Benefit-harm trade-offs of intensive blood pressure control versus standard blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of randomised controlled trials.
    Lancet. 2025 Aug 28:S0140-6736(25)01391-1. doi: 10.1016/S0140-6736(25)01391.
    PubMed     Abstract available
    
    
    May 2025
14. FRIEDEN TR, Garg R, Moran AE, Whelton PK, et al
    Improved hypertension care requires measurement and management in health facilities, not mass screening.
    Lancet. 2025 May 7:S0140-6736(25)00561-6. doi: 10.1016/S0140-6736(25)00561.
    PubMed     Abstract available
    
    
    January 2025
15. MCCARTHY CP, Bruno RM, Rahimi K, Touyz RM, et al
    Global and European landscape of major hypertension guidelines.
    Lancet. 2025 Jan 15:S0140-6736(24)02795-8. doi: 10.1016/S0140-6736(24)02795.
    PubMed    
    
    
    October 2024
16. RODGERS A, Salam A, Schutte AE, Cushman WC, et al
    Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical tria
    Lancet. 2024;404:1536-1546.
    PubMed     Abstract available
    
    
    
17. ANTONOPOULOU M, Chliveros K
    A novel low-dose triple single-pill combination for hypertension.
    Lancet. 2024;404:1496-1498.
    PubMed    
    
    
    August 2024
18. 
    General and abdominal adiposity and hypertension in eight world regions: a pooled analysis of 837 population-based studies with 7.5 million participants.
    Lancet. 2024;404:851-863.
    PubMed     Abstract available
    
    
    July 2024
19. WERNHART M, Wiesinger C, Windpessl M, Madl-Liebenberger L, et al
    A visual diagnosis of phaeochromocytoma crisis characterised by cyclic fluctuations of blood pressure: be on the look-out for rapid changes.
    Lancet. 2024;404:375-376.
    PubMed    
    
    
    
20. RAHIMI K
    Mounting evidence in favour of the lower, the better blood pressure paradigm.
    Lancet. 2024;404:216-217.
    PubMed    
    
    
    June 2024
21. LIU J, Li Y, Ge J, Yan X, et al
    Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial.
    Lancet. 2024 Jun 27:S0140-6736(24)01028-6. doi: 10.1016/S0140-6736(24)01028.
    PubMed     Abstract available
    
    
    
22. HAYASHI SI, Kawano Y, Morishita R, Kusano KF, et al
    Time-lagged amelioration of vascular endothelial function in malignant hypertension: different organs improved at different rates.
    Lancet. 2024;403:2630-2631.
    PubMed    
    
    
    May 2024
23. JAFFAR S
    Integrated HIV, diabetes, and hypertension care in sub-Saharan Africa - Authors' reply.
    Lancet. 2024;403:2292.
    PubMed    
    
    
    
24. CAI S, Xu Z, Zhao Y, Zuhlke L, et al
    Integrated HIV, diabetes, and hypertension care in sub-Saharan Africa.
    Lancet. 2024;403:2291.
    PubMed    
    
    
    
25. HAVLIR D, Kamya MR, Petersen M
    Integrated HIV, diabetes, and hypertension care in sub-Saharan Africa.
    Lancet. 2024;403:2291-2292.
    PubMed    
    
    
    March 2024
26. BAUDIN E, Goichot B, Berruti A, Hadoux J, et al
    Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial.
    Lancet. 2024;403:1061-1070.
    PubMed     Abstract available
    
    
    
27. DE LA SIERRA A, Staplin N, Ruilope LM, Baigent C, et al
    Ambulatory blood pressure monitoring and mortality - Authors' reply.
    Lancet. 2024;403:812.
    PubMed    
    
    
    
28. LIU W, Ge W, Fan X, Du Y, et al
    Ambulatory blood pressure monitoring and mortality.
    Lancet. 2024;403:811-812.
    PubMed    
    
    
    
29. MARTINEZ-GARCIA MA, Pengo MF, Parati G
    Ambulatory blood pressure monitoring and mortality.
    Lancet. 2024;403:810-811.
    PubMed    
    
    
    
30. CHU WM, Ho HE, Wei JC
    Ambulatory blood pressure monitoring and mortality.
    Lancet. 2024;403:810.
    PubMed    
    
    
    
31. LI SQ, Zhou JP, Wang Y, Li QY, et al
    Ambulatory blood pressure monitoring and mortality.
    Lancet. 2024;403:809-810.
    PubMed    
    
    
    November 2023
32. JACKSON R, Rodgers A
    The ESH guidelines and missed prevention opportunities.
    Lancet. 2023;402:1729-1730.
    PubMed    
    
    
    October 2023
33. MESSERLI FH, Bangalore S, Mandrola JM
    beta blockers switched to first-line therapy in hypertension.
    Lancet. 2023 Oct 13:S0140-6736(23)01733-6. doi: 10.1016/S0140-6736(23)01733.
    PubMed     Abstract available
    
    
    
34. KIVUYO S, Birungi J, Okebe J, Wang D, et al
    Integrated management of HIV, diabetes, and hypertension in sub-Saharan Africa (INTE-AFRICA): a pragmatic cluster-randomised, controlled trial.
    Lancet. 2023;402:1241-1250.
    PubMed     Abstract available
    
    
    
35. KISIGO GA, Peck RN
    Integrating HIV, hypertension, and diabetes primary care in Africa.
    Lancet. 2023;402:1211-1213.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hypertension is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum